Acid-Activated Peptide Delivers Cancer Drug Directly Into Tumor Cell Nuclei
A pH-sensitive cell-penetrating peptide (HNLS-3) with nuclear localization capacity delivered camptothecin into cancer cell nuclei with enhanced cytotoxicity and selectivity versus the free drug.
Quick Facts
What This Study Found
HNLS-3 displayed pH-dependent cellular uptake, endosomal escape, and nuclear localization. HNLS-3-CPT conjugate showed enhanced cytotoxicity and selectivity compared to free CPT.
Key Numbers
6 His residues; PFVYLI sequence; NLS; enhanced CPT cytotoxicity; improved selectivity; pH-dependent activation
How They Did This
Peptide design combining 6 histidine residues, hydrophobic sequence PFVYLI, and nuclear localization sequence. pH-dependent uptake, endosomal escape, and nuclear localization assessed. Cytotoxicity of peptide-drug conjugate versus free drug measured.
Why This Research Matters
Many cancer drugs work in the nucleus but can't get there efficiently. A peptide that activates in acidic tumors AND delivers drugs to the nucleus solves two delivery problems simultaneously.
The Bigger Picture
Smart peptide delivery systems that respond to tumor-specific conditions (like acidity) and target specific subcellular compartments (like the nucleus) represent the next frontier in precision drug delivery.
What This Study Doesn't Tell Us
In vitro cancer cell study only. No animal tumor models tested. Peptide stability in blood and biodistribution unknown. Manufacturing complexity of peptide-drug conjugates.
Questions This Raises
- ?Would HNLS-3 deliver camptothecin effectively in vivo tumor models?
- ?Can this dual-targeting approach (tumor pH + nucleus) be applied to other nuclear-acting drugs?
- ?How does the peptide-drug conjugate stability compare in blood versus tumor tissue?
Trust & Context
- Key Stat:
- pH-activated + nuclear-targeted HNLS-3 activates in acidic tumors, escapes endosomes, and delivers drug cargo directly to the cancer cell nucleus — triple-targeting in one peptide
- Evidence Grade:
- Low evidence grade: in vitro proof-of-concept with no animal data.
- Study Age:
- Published 2021. Stimulus-responsive CPPs continue to advance for targeted cancer therapy.
- Original Title:
- Design of acid-activated cell-penetrating peptides with nuclear localization capacity for anticancer drug delivery.
- Published In:
- Journal of peptide science : an official publication of the European Peptide Society, 27(10), e3354 (2021)
- Authors:
- Huang, Sujie(2), Zhu, Zhongwen, Jia, Bo(2), Zhang, Wei, Song, Jingjing
- Database ID:
- RPEP-05453
Evidence Hierarchy
Frequently Asked Questions
Why target the cell nucleus with cancer drugs?
Many cancer drugs like camptothecin work by damaging cancer cell DNA, which is in the nucleus. If the drug gets stuck in other parts of the cell, it's less effective and may cause more side effects. Delivering it directly to the nucleus maximizes cancer-killing while minimizing waste.
How does the peptide know to activate in tumors?
Tumors are more acidic than normal tissue (pH ~6.5 vs ~7.4). The peptide contains histidine residues that change their charge at low pH, switching on the peptide's cell-penetrating ability specifically in the acidic tumor environment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05453APA
Huang, Sujie; Zhu, Zhongwen; Jia, Bo; Zhang, Wei; Song, Jingjing. (2021). Design of acid-activated cell-penetrating peptides with nuclear localization capacity for anticancer drug delivery.. Journal of peptide science : an official publication of the European Peptide Society, 27(10), e3354. https://doi.org/10.1002/psc.3354
MLA
Huang, Sujie, et al. "Design of acid-activated cell-penetrating peptides with nuclear localization capacity for anticancer drug delivery.." Journal of peptide science : an official publication of the European Peptide Society, 2021. https://doi.org/10.1002/psc.3354
RethinkPeptides
RethinkPeptides Research Database. "Design of acid-activated cell-penetrating peptides with nucl..." RPEP-05453. Retrieved from https://rethinkpeptides.com/research/huang-2021-design-of-acidactivated-cellpenetrating
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.